Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Thermal Therapy + Targeted/Immunotherapy vs Targeted/Immunotherapy in Unresectable HCC
NCT07596134Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhejiang University. Primary endpoint: Progression-free survival per mRECIST at 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07596134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596134.